

MEDICINES360 IS A NONPROFIT  
PHARMACEUTICAL ORGANIZATION  
DEDICATED TO WOMEN'S HEALTH

# This is Honorina,

## Unique Business Model



a 27 year-old Malagasy woman studying to become a seamstress. Honorina wants to protect herself from getting pregnant until she is ready. Honorina stopped using injectables because it was too tough to make it to the clinic every three months. She used the rhythm method but worried the method didn't provide enough protection. Honorina tried using implants too, but was dissatisfied because the method caused more menstrual bleeding for her. In 2018, a family planning educator told her about the range of methods and described how **Avibela™ can address heavy periods, which attracted Honorina to the method.** Now, Honorina can continue her studies without the stress of getting pregnant.



**Avibela™**  
(levonorgestrel-releasing intrauterine system) 52 mg

## Our Mission

Catalyze **equitable access** to **medicines and devices** through **product development, policy advocacy,** and collaboration with **global and U.S. partners**



For questions OR to learn more  
ABOUT AVIBELA, VISIT [AVIBELA.COM](https://www.avibela.com) OR  
EMAIL [GLOBALACCESS@MEDICINES360.ORG](mailto:GLOBALACCESS@MEDICINES360.ORG)

Avibela® is a registered trademark of Medicines360 in countries across Africa, South and Southeast Asia, Central America, and the Caribbean  
Impact RH360® is a registered trademark of Medicines360 in Madagascar, Rwanda, Uganda, South Africa, and Zambia.  
Medicines360® and its design are registered marks of Medicines360.  
© 2022 Medicines360. All rights reserved.

**OUR IUD WAS APPROVED  
BY THE U.S. FDA IN 2015**

*We are expanding access*

to our IUD in Africa, South and Southeast Asia, Central America, and the Caribbean, under the brand Avibela™

AVIBELA is manufactured in Belgium and supplied to global and local partners by Medicines360

Local partners lead distribution, training, and service delivery

AVIBELA is available at a subsidized access price for all units ordered through international procurement group catalogs or on behalf of eligible public sector programs



# Avibela™

(levonorgestrel-releasing intrauterine system) 52 mg

## KEY CLINICAL CHARACTERISTICS

**AVIBELA is a hormonal IUD indicated for contraception and heavy menstrual bleeding, with durations of use up to 6 years depending on local regulatory approvals**

- The mechanism of action for contraception is thickening of cervical mucus that inhibits the passage of sperm<sup>1</sup>
- The mechanism of action for treatment of heavy menstrual bleeding is thinning of the uterine lining<sup>1</sup>



**Highly effective long-acting reversible contraceptive**

- >99% effective at preventing pregnancy for up to six years<sup>1</sup>

**Effective at treating heavy menstrual bleeding**

- Women with heavy menstrual bleeding experience an 88% decrease in the volume of menstrual bleeding by the end of three months of use, and an 82% reduction is sustained for 12 months (based on a 12-month study)<sup>1</sup>

**Does not alter fertility after removal**

- 99% of women experience return to menses by three months after IUD removal<sup>1</sup>
- 79% of women desiring pregnancy conceive within six months of IUD removal; 85% of women conceive within 12 months<sup>1</sup>

**Studied in a broad range of women**

- 1,751 women ages 16-45<sup>2</sup>
- 58% nulliparous (having never given birth)<sup>2</sup>
- BMI range 16-62 and average 27<sup>2</sup>

**Same-day insertion is possible**

- Can be inserted at any time, including the same day as the initial visit to the clinic (if the provider is reasonably certain the woman is not pregnant)<sup>2</sup>

<sup>1</sup> AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg [Summary of Product Characteristics and Prescribing Information]. Impact RH360; 2022.

<sup>2</sup> Eisenberg, D. et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. *Contraception* 92 (2015) 10-16.